Rhophylac Market Report 2026

Rhophylac Market Overview

• The Rhophylac market growth in the historic period has been driven by expansion of prenatal care services, adoption of routine rh immunoglobulin administration • Market expansion is supported by rising demand for preventive maternal therapies, expansion of high-risk pregnancy management programs • Growth Driver: Rising Awareness Of Blood Safety Driving Market Growth Due To Increasing Adoption Of Immunoglobulin Therapies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Rhophylac Market?

Rhophylac is a human anti-D immunoglobulin used to prevent Rh immunization in Rh-negative individuals exposed to Rh-positive red blood cells. It is commonly administered during pregnancy, after childbirth, or following blood transfusions to avoid complications like hemolytic disease of the newborn. The main types of indications in rhophylac are suppression of Rh isoimmunization, incompatible transfusions, and immune thrombocytopenic purpura (ITP). Suppression of Rh isoimmunization involves administering Rh immunoglobulin (RhIg) to a Rh-negative mother to prevent her immune system from producing antibodies against Rh-positive fetal blood cells, thus reducing the risk of complications in future pregnancies. It is administered via intravenous (IV) and intramuscular (IM) routes and distributed through various channels such as hospitals, clinics, and pharmacies. The various end users include pediatric, adult, and geriatric.

What Is The Rhophylac Market Growth Forecast?

The growth in the forecast period can be attributed to rising demand for preventive maternal therapies, expansion of high-risk pregnancy management programs, increasing focus on reducing hemolytic disease incidence, growth of specialty plasma therapies, strengthening of transfusion safety standards. Major trends in the forecast period include increasing use of prophylactic anti-d therapies, rising awareness of rh incompatibility risks, expansion of maternal screening programs, improved plasma-derived product safety, enhanced focus on obstetric care protocols.

Global Rhophylac Market Segmentation

1) By Indication: Suppression Of Rh Isoimmunization, Incompatible Transfusions, Immune Thrombocytopenic Purpura (ITP) 2) By Administration: Intravenous (IV), Intramuscular (IM) 3) By Distribution Channel: Hospitals, Clinics, Pharmacies 4) By End User: Pediatric, Adult, Geriatric

What Are The Drivers Of The Rhophylac Market?

The rising awareness of blood safety is expected to propel the growth of the rhophylac market going forward. Blood safety refers to the measures and practices designed to prevent contamination and infection transmission, ensuring the safety of blood and blood products through donor screening, disease testing, proper storage, and handling. The rising awareness of blood safety can be attributed to factors such as increased public health campaigns, advancements in blood screening technologies, stricter regulatory standards, global health crises, rising incidents of bloodborne diseases, and enhanced medical training. Rhophylac helps raise awareness of blood safety by preventing Rh incompatibility in pregnant women, ensuring safe blood management, and reducing the risk of hemolytic disease of the newborn. For instance, in August 2023, according to the Royal College of Pathologists, a UK-based organization, blood transfusion is the most frequently performed procedure for hospitalized patients, with nearly 2 million blood components issued and transfused in England annually, costing over £300 ($390.69) million. Therefore, rising awareness of blood safety is driving the growth of the rhophylac industry. The growing number of organ transplants is expected to propel the growth of the rhophylac market going forward. Organ transplants refer to the medical procedure of replacing a damaged or failing organ in a patient’s body with a healthy one from a donor to save or improve the patient’s life. The growing number of organ transplants can be attributed to factors such as advancements in medical technology, improved surgical techniques, better post-transplant care, increasing organ donor awareness, and rising rates of chronic diseases like kidney failure, heart disease, and liver cirrhosis. Rhophylac is used in organ transplants to prevent immune rejection and alloimmunization by providing passive immunization with Rh immunoglobulin, reducing sensitization to foreign antigens. For instance, in January 2025, according to the Organ Procurement and Transplantation Network, a US-based non-profit organization, there was a modest rise in kidney transplants, reaching 27,759 in 2024, an increase of 1.6 percent compared to 2023. In contrast, the number of heart transplants remained nearly the same, with 4,572 procedures in 2024 compared to 4,545 in 2023. Therefore, the rising number of organ transplants is driving the growth of the rhophylac industry. The increasing healthcare expenditure is expected to propel the growth of the rhophylac market going forward. Healthcare expenditure refers to the total amount spent on healthcare services and products within a specific period. The increase in healthcare expenditure is driven by factors including aging populations, advancements in medical technology, and rising demand for healthcare services. Rhophylac, a human immune globulin, helps reduce healthcare expenditure by preventing Rh incompatibility-related complications in pregnancy, thereby avoiding costly treatments for hemolytic disease of the newborn. For instance, in July 2024, according to Statistics Austria, an Austria-based federal agency, in 2023, Austria's healthcare expenditure reached $56.47 billion (€52.28 billion), accounting for 10.9% of the nation's GDP. This represents a year-on-year increase of $2.57 billion (€2.38 billion), or 4.8%, compared to 2022. Therefore, the rising healthcare expenditure is driving the growth of the rhophylac industry.

Key Players In The Global Rhophylac Market

Major companies operating in the rhophylac market are CSL Behring AG

Regional Insights

North America was the largest region in the rhophylac market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Rhophylac Market?

The rhophylac market consists of sales of injections, vials, pre-filled syringes, rh immunoglobulin products, and companion products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Rhophylac Market Report 2026?

The rhophylac market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the rhophylac industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.